Search Bar & Filters
Found 5 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the long-term safety and tolerability of dazodalibep in people with Sjgrens Syndrome. This phase 3 open-label study extends previous trials by continuing to monitor participants who completed 48 weeks of treatment with dazodalibep or placebo. The study is sponsored by Amgen and aims to better understand the safety profile of dazodalibep over an extended period. Participants who finished the initial 48-week trials HZNP-DAZ-301 or HZNP-DAZ-303 will receive an assigned dose of dazodalibep intravenously for an additional 132 weeks. This extension study involves a single treatment group receiving dazodalibep without placebo, focusing on ongoing treatment effects and participant safety. During the study, participants will be monitored for treatment-emergent adverse events for up to 152 weeks. Researchers will also measure the presence of anti-drug antibodies and plasma concentrations of dazodalibep for up to 132 weeks. Participants need to be available for all study visits and procedures, with safety assessments conducted regularly throughout the long-term extension period.
Actively Recruiting
The trial investigates the long-term safety of avacopan in adults diagnosed with antineutrophil cytoplasmic antibody ANCA-associated vasculitis, a condition requiring immunosuppressive treatment. This phase 4, randomized, double-blind, placebo-controlled study aims to assess treatment-emergent adverse events and other safety markers over a period of up to 5 years. Participants include those newly diagnosed or experiencing a relapse of granulomatosis with polyangiitis or microscopic polyangiitis, with specific antibody and disease activity criteria. Participants are randomly assigned to one of three groups avacopan 30 mg twice daily for 5 years with standard immunosuppressive therapy, avacopan 30 mg twice daily for 1 year followed by placebo for 4 years with standard therapy, or placebo twice daily for 5 years with standard therapy. All participants receive background immunosuppressive care as determined by their doctors. Treatments are administered orally, and the study maintains double-blinding to compare safety and efficacy outcomes across groups. Throughout the study, participants undergo regular safety assessments including vital signs, blood tests, serum chemistry, and urine analysis to monitor any significant changes from baseline. Researchers evaluate adverse events, remission status, kidney function, health survey scores, and glucocorticoid or immunosuppressant use over the 5-year period. The study includes continuous monitoring for serious adverse events, treatment withdrawals, and deaths related to the intervention, ensuring detailed long-term safety data collection.
Actively Recruiting
Researchers are evaluating the potential benefits and risks of active sub-threshold wireless neuromodulation stimulation for treating chronic knee pain caused by osteoarthritis. This trial aims to compare active stimulation versus no stimulation sham in reducing pain, with the primary goal of measuring the number of participants who experience at least a 50% decrease in pain on a visual analog scale after one month. Participants first undergo a diagnostic injection to confirm temporary pain relief before receiving a 7-day trial implant of the stimulation device near the target nerve. Those reporting more than 50% pain relief during this test proceed to receive a permanent implant under sedation. After a healing period of 10 days, participants are randomized to receive either active sub-threshold stimulation or sham stimulation for 30 days while both participants and staff remain unaware of group assignments. Stimulation programs include various high-frequency options. Throughout the study, participants attend in-person visits at 1 week, 1 month, 3 months, and 6 months post-randomization for physical exams, pain scales, knee function assessments, range of motion, work status, and medication use. Additional phone follow-ups are conducted at 12, 18, and 24 months to assess long-term pain relief and any adverse events. The study collects multiple outcome measures to evaluate the treatments impact on pain and physical function over time.
Actively Recruiting
Researchers are studying Medicare beneficiaries with Lumbar Spinal Stenosis LSS and Neurogenic Claudication NC to compare outcomes after two different procedures MILD Percutaneous Image-Guided Lumbar Decompression and Interspinous Process Decompression IPD. This observational study tracks patients treated since January 1, 2017, evaluating the rates of surgical and minimally invasive interventions as well as any harms related to these procedures over 24 months. The study uses Medicare claims data and does not require prior patient consent or IRB oversight. The study includes two groups of patients those who received the MILD procedure, involving partial decompression under image guidance by removing tissue and bone at the affected spinal level, and those who underwent IPD, a device-based decompression technique. Both groups are observed through Medicare data for two years after their initial procedure to assess the need for further surgeries or interventions and to monitor for any complications. Participants are followed for 24 months after their index procedure using Medicare claims data. Researchers monitor the rates of harms associated with the initial treatment and the frequency of additional surgical or minimally invasive interventions. Since this is an observational study, data collection relies on existing Medicare records without direct patient involvement, and the study will continue enrolling patients until the sponsor stops it.
Actively Recruiting
Researchers are evaluating a stepped care approach called STARRS-PC Stepped Approach to Reducing Risk of Suicide in Primary Care to reduce suicide risk among youth aged 12 to 17 years receiving primary care. This study aims to compare the effectiveness of STARRS-PC against usual treatment TAU in lowering suicide attempts, suicidal thoughts, and self-injury over a 12-month period. The study also explores factors that affect how well the clinical pathway can be put into practice and sustained in primary care settings. The study is conducted over five years at 14 pediatric primary care clinics. It includes three phases treatment as usual TAU, intervention, and sustainability. During TAU, usual depression and suicide risk screening is performed. In the intervention phase, STARRS-PC is implemented, which involves universal suicide risk screening with a brief questionnaire, followed by a detailed risk assessment and care decisions based on risk level. Providers receive training and participate in interviews to identify challenges and supports for implementing the clinical care pathway. The final sustainability phase focuses on maintaining improvements without enrolling new participants. Participants include 2,572 adolescents identified at risk for suicide along with their parents or guardians. They complete interviews and questionnaires at baseline, 3, 6, and 12 months. Medical records are reviewed throughout the study. Youth outcomes measured include suicide attempts, suicidal thoughts, and non-suicidal self-injury, while family satisfaction is also assessed. Providers are evaluated on knowledge and attitudes about suicide risk management. The study includes ongoing monitoring, data collection, and a 6-month follow-up after the intervention phase for sustainability analysis.